- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Patent holdings for IPC class C07D 209/42
Total number of patents in this class: 722
10-year publication summary
|
48
|
53
|
47
|
52
|
47
|
36
|
45
|
38
|
40
|
25
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Achillion Pharmaceuticals, Inc. | 157 |
26 |
| Boehringer Ingelheim International GmbH | 4493 |
15 |
| Vertex Pharmaceuticals Incorporated | 1578 |
12 |
| Novartis AG | 10251 |
10 |
| Kissei Pharmaceutical Co., Ltd. | 177 |
10 |
| Hoffmann-La Roche Inc. | 3796 |
9 |
| Les Laboratoires Servier | 498 |
9 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3003 |
9 |
| F. Hoffmann-La Roche AG | 7819 |
8 |
| Glaxosmithkline Intellectual Property (no.2) Limited | 308 |
7 |
| Astellas Pharma Inc. | 1043 |
7 |
| Allergan, Inc. | 2162 |
6 |
| FUJIFILM Corporation | 30516 |
6 |
| Takeda Pharmaceutical Company Limited | 2710 |
6 |
| Oxford University Innovation Limited | 1666 |
6 |
| Rutgers, The State University of New Jersey | 1972 |
6 |
| Sunshine Lake Pharma Co., Ltd. | 628 |
6 |
| Vanderbilt University | 2022 |
6 |
| Bristol-myers Squibb Company | 4751 |
5 |
| Abbvie Inc. | 1824 |
5 |
| Other owners | 548 |